retatrutide clinical trial availability for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational trials - Giblin - 2026 - Diabetes, Obesity and Metabolism Reta clinical trial data &
Description
The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases
Scorrano et al., 2019)
95% CI: 0.871.35) compared to sulfonylureas
The glucagon component likely drives this through increased hepatic fat oxidation
However, it makes sense that obesity could affect disease course, as obesity is associated with chronic, systemic inflammation
